Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial
Michael J. Kovacs(Western University), Marc Rodger(McGill University), David R. Anderson(Dalhousie University), Shannon M. Bates(McMaster University), Elham Sabri(Ottawa Hospital), Susan Solymoss(Montreal General Hospital), Alejandro Lazo‐Langner(Western University), Susan R. Kahn(Jewish General Hospital), Erik Yeo(University Health Network), Sam Schulman(Thrombosis and Atherosclerosis Research Institute), Philip S. Wells(Ottawa Hospital), Clive Kearon(McMaster University), Mark Blostein(Jewish General Hospital), Tim Ramsay(University of Ottawa)
Cited by 105
Related Papers
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
|Journal of Thrombosis and Haemostasis|2005|4.9k
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
|Journal of Thrombosis and Haemostasis|2009|3.8k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Prevention of VTE in Nonsurgical Patients
|CHEST Journal|2012|2.7k
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
|New England Journal of Medicine|2009|2.6k